EGFR and non-small cell lung carcinoma: A critical role for oncogenic mutations is illustrated by the example of epidermal growth factor receptor (EGFR/ERBB1) in Non Small Cell Lung Cancer (NSCLC), where only a subset of patients respond to the EGFR inhibitor gefitinib.